Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New oral drug shows promise for painful skin condition

NCT ID NCT05620823

Disease control Sponsor: Incyte Corporation Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 3 trial tested the drug povorcitinib in 608 people with moderate to severe hidradenitis suppurativa, a chronic skin condition causing painful lumps and abscesses. Participants received either the drug or a placebo for 12 weeks, followed by a 42-week extension where everyone could get the drug. The main goal was to see if the drug could reduce abscess and inflammatory nodule counts by at least 50% without worsening other symptoms.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
povorcitinib (a JAK inhibitor taken as a pill)
What this could lead to
If it works, this could provide a new oral treatment option to reduce painful lumps and abscesses in people with hidradenitis suppurativa.
What could go wrong
This is a completed phase 3 trial, but results are not yet published. The drug may not work better than placebo, and JAK inhibitors carry risks like infection and blood clots.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

608 people

The number who actually took part.

Started

Dec 2022

Finished

Dec 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Diagnosis of moderate to severe HS for at least 3 months prior to the screening visit. * Total abscess and inflammatory nodule count of at least 5 at both the screening and baseline visits * HS lesions in at least 2 distinct anatomical areas (examples include but are not limited to left and right axilla or left and right inguinocrural fold), 1 of which must be at least Hurley Stage II or Hurley Stage III, at both the screening and baseline visits * Documented history of inadequate response to at least a 3-month course of at least 1 conventional systemic therapy (oral antibiotic or biologic drug) for HS (or demonstrated intolerance to, or have a contraindication to, a conventional systemic therapy for treatment of their HS). * Agreement to NOT use topical and systemic antibiotics for treatment of HS during the placebo-controlled period. * Agreement to NOT use a diluted bleach bath or topical antiseptic washes containing chlorhexidine gluconate or benzoyl peroxide on the areas affected by HS lesions during the placebo-controlled period. Note: Over-the-counter soap and water is allowed. * Agreement to use contraception * Willing and able to comply with the study protocol and procedures. * Further inclusion criteria apply. Exclusion Criteria: * Presence of \> 20 draining tunnels (fistulas) at either the screening or baseline visit. * Women who are pregnant (or who are considering pregnancy) or breastfeeding. * Medical history including thrombocytopenia, coagulopathy or platelet dysfunction, Q-wave interval abnormalities, current or history of certain infections, cancer, lymphoproliferative disorders and other medical conditions at the discretion of the investigator. * Laboratory values outside of the protocol-defined ranges. * Further exclusion criteria apply.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hidradenitis suppurativa (HS) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

hidradenitis hidradenitis suppurativa

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hidradenitis suppurativa (HS)

Contacts and locations

Locations

  • Investigative Site 00A

    Innsbruck, 06020, Austria

  • Investigative Site AT300

    Vienna, 01130, Austria

  • Investigative Site AT301

    Vienna, 01100, Austria

  • Investigative Site AT302

    Linz, 04020, Austria

  • Investigative Site AT304

    Graz, 08036, Austria

  • Investigative Site AT305

    Vienna, 01090, Austria

  • Investigative Site AT306

    Innsbruck, 06020, Austria

  • Investigative Site BE300

    Brussels, 01070, Belgium

  • Investigative Site BE301

    Ghent, 09000, Belgium

  • Investigative Site BE302

    Liège, 04000, Belgium

  • Investigative Site BE303

    Namur, 05000, Belgium

  • Investigative Site BE304

    Brussels, 01200, Belgium

  • Investigative Site BE305

    Leuven, 03000, Belgium

  • Investigative Site BE306

    Ghent, 09000, Belgium

  • Investigative Site CA301

    Winnipeg, Manitoba, R3M 3Z4, Canada

  • Investigative Site CA302

    Peterborough, Ontario, K9J 5K2, Canada

  • Investigative Site CA303

    London, Ontario, N6H 5L5, Canada

  • Investigative Site CA304

    Barrie, Ontario, L4M 1G7, Canada

  • Investigative Site CA306

    Laval, Quebec, H7N 6L2, Canada

  • Investigative Site CA307

    Montreal, Quebec, H2K 4L5, Canada

  • Investigative Site CA308

    Hamilton, Ontario, L8L 3C3, Canada

  • Investigative Site CA309

    Québec, Quebec, G1V 4T3, Canada

  • Investigative Site CZ300

    Prague, 150 06, Czechia

  • Investigative Site CZ301

    Ostrava - Poruba, 708 52, Czechia

  • Investigative Site DE300

    Hanover, 30519, Germany

  • Investigative Site DE301

    Frankfurt am Main, 60590, Germany

  • Investigative Site DE302

    Dresden, 01307, Germany

  • Investigative Site DE303

    Hamburg, 20246, Germany

  • Investigative Site DE304

    Langenau, 89129, Germany

  • Investigative Site DE305

    Darmstadt, 64283, Germany

  • Investigative Site DE306

    Düsseldorf, 40225, Germany

  • Investigative Site DE307

    Memmingen, 87700, Germany

  • Investigative Site ES300

    Pontevedra, 36001, Spain

  • Investigative Site ES301

    Granada, 18014, Spain

  • Investigative Site ES302

    Badalona, 08916, Spain

  • Investigative Site ES303

    Barcelona, 08003, Spain

  • Investigative Site ES304

    Santiago de Compostela, 15706, Spain

  • Investigative Site ES305

    Madrid, 28041, Spain

  • Investigative Site FR300

    Paris, 75010, France

  • Investigative Site FR301

    Saint-Priest-en-Jarez, 42270, France

  • Investigative Site FR302

    Nantes, 44093, France

  • Investigative Site FR303

    Brest, 29609, France

  • Investigative Site FR304

    Marseille, 13385, France

  • Investigative Site FR305

    Bordeaux, 33000, France

  • Investigative Site FR306

    Toulouse, 31059, France

  • Investigative Site FR307

    Le Mans, 72037, France

  • Investigative Site GR300

    Athens, 12462, Greece

  • Investigative Site GR301

    Thessaloniki, 54643, Greece

  • Investigative Site GR302

    Thessaloniki, 56403, Greece

  • Investigative Site GR303

    Athens, 16121, Greece

  • Investigative Site JP300

    Kyoto, 602-8566, Japan

  • Investigative Site JP301

    Nakagami-gun, 903-0215, Japan

  • Investigative Site JP302

    Sendai, 980-8574, Japan

  • Investigative Site JP303

    Niigata, 951-8520, Japan

  • Investigative Site JP304

    Itabashi-ku, 173-8610, Japan

  • Investigative Site JP305

    Kurume-shi, 830-0011, Japan

  • Investigative Site JP306

    Tsukuba, 305-8576, Japan

  • Investigative Site JP307

    Nishinomiya-shi, 663-8186, Japan

  • Investigative Site JP308

    Sapporo, 060-8648, Japan

  • Investigative Site JP309

    Shinjuku-ku, 160-0023, Japan

  • Investigative Site NL301

    Rotterdam, 3015 GD, Netherlands

  • Investigative Site NL302

    Breda, 4818 CK, Netherlands

  • Investigative Site NL303

    Groningen, 9713 GZ, Netherlands

  • Investigative Site PL301

    Wroclaw, 50-566, Poland

  • Investigative Site PL302

    Wroclaw, 51-318, Poland

  • Investigative Site PL303

    Poznan, 60-529, Poland

  • Investigative Site PL304

    Ostrowiec, 27-400, Poland

  • Investigative Site US300

    Plano, Texas, 75025, United States

  • Investigative Site US301

    Portland, Oregon, 97223, United States

  • Investigative Site US302

    St Louis, Missouri, 63110, United States

  • Investigative Site US303

    Phoenix, Arizona, 85006, United States

  • Investigative Site US304

    Boston, Massachusetts, 02215, United States

  • Investigative Site US306

    Boca Raton, Florida, 33486, United States

  • Investigative Site US307

    Fort Smith, Arkansas, 72916, United States

  • Investigative Site US308

    Spokane, Washington, 99202, United States

  • Investigative Site US310

    Brighton, Massachusetts, 02135, United States

  • Investigative Site US311

    Marietta, Georgia, 30060-1047, United States

  • Investigative Site US312

    Cleveland, Ohio, 44106, United States

  • Investigative Site US313

    Norfolk, Virginia, 23502, United States

  • Investigative Site US314

    Cincinnati, Ohio, 45219, United States

  • Investigative Site US315

    Laguna Niguel, California, 92677, United States

  • Investigative Site US316

    Orlando, Florida, 32819, United States

  • Investigative Site US317

    Hialeah, Florida, 33012-3618, United States

  • Investigative Site US318

    Beverly, Massachusetts, 01915, United States

  • Investigative Site US319

    Skokie, Illinois, 60077, United States

  • Investigative Site US320

    Boca Raton, Florida, 33486, United States

  • Investigative Site US321

    North Miami Beach, Florida, 33162-4708, United States

  • Investigative Site US323

    San Francisco, California, 94118, United States

  • Investigative Site US324

    Kew Gardens, New York, 11415, United States

  • Investigative Site US325

    Columbia, Maryland, 21045, United States

  • Investigative Site US326

    Los Angeles, California, 90045, United States

  • Investigative Site US327

    Chicago, Illinois, 60612, United States

  • Investigative Site US328

    Tampa, Florida, 33612, United States

  • Investigative Site US330

    Boardman, Ohio, 44512, United States

  • Investigative Site US331

    Albuquerque, New Mexico, 87102, United States

  • Investigative Site US333

    Baltimore, Maryland, 21287, United States

  • Investigative Site US334

    Metairie, Louisiana, 70006, United States

  • Investigative Site US335

    Arkansas City, Arkansas, 72758, United States

  • Investigative Site US336

    Tampa, Florida, 33613, United States

  • Investigative Site US337

    Indianapolis, Indiana, 46250, United States

  • Investigative Site US338

    Margate, Florida, 33063, United States

  • Investigative Site US339

    Bexley, Ohio, 43209, United States

  • Investigative Site US340

    Bellaire, Texas, 77401, United States

  • Investigative Site US341

    Bowling Green, Kentucky, 42103, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.